Evaluating only Vincera Pharma’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Vincera Pharma founded in Philadelphia to develop CDK9 inhibitors for hematologic malignancies.
Phase 1/2 data shows 35% incidence of Grade 3+ pneumonitis and colitis; FDA advises dose reduction strategy review.
ACQUISITION ATTEMPT
Vincera merges with Equillium in distressed deal after Nasdaq delisting notice; VIP152 program effectively shelved.
Full Analysis
Free · no account needed
Documented cause
Vincera Pharma, a Philadelphia-based oncology biotech developing PI3K delta inhibitor VIP152 for hematologic cancers, merged with Equillium in late 2022 in a distressed deal after Phase 1/2 data showed severe immune toxicity including pneumonitis and colitis in 35% of patients. CEO Ian Henig announced the strategic pivot to Equillium after Vincera's Nasdaq stock fell below $1 and the company received a delisting notice in August 2022, having spent $58M of raised capital.
Lesson
“PI3K delta inhibitors have predictable immune toxicity; plan dose-limiting toxicity management before Phase 2 expansion.”